Executive Order 14293 aims to eliminate regulatory barriers to domestic pharmaceutical production, framing itself as a continuation of efforts begun in the President's first term (specifically referencing Executive Order 13944 of August 6, 2020). The order identifies what it characterizes as critical national security vulnerabilities in the pharmaceutical supply chain, claiming the previous administration "did too little" to address these issues. It highlights the lengthy timeline (estimated at 5-10 years) currently required to build pharmaceutical manufacturing facilities in the United States as "unacceptable from a national security standpoint," attributing these delays to overlapping federal, state, and local requirements. The order also notes that domestic facilities face more frequent unannounced FDA inspections than their international counterparts, which it presents as a competitive disadvantage.
The order directs multiple federal agencies to streamline regulations affecting domestic pharmaceutical manufacturing within specific timeframes. The FDA Commissioner is instructed to complete a comprehensive review within 180 days to eliminate duplicative requirements, improve inspection protocols, expand technical advice programs, enhance enforcement of data reporting, clarify guidance for production transfers from foreign to domestic facilities, and update compliance policies. Within 90 days, the FDA must also develop improvements to overseas facility inspections, funded by increased fees on foreign manufacturers, and publicly disclose annual inspection data by country and manufacturer. Similarly, the EPA Administrator is given 180 days to update regulations affecting pharmaceutical manufacturing approvals, while the Army Corps of Engineers must review nationwide permits to determine if specific permitting is needed for pharmaceutical facilities.
The implementation structure designates the EPA as the lead agency for permitting pharmaceutical manufacturing facilities requiring Environmental Impact Statements (unless another agency assumes this role), with requirements to establish a single point of contact for permit applicants. The Office of Management and Budget is tasked with coordinating between relevant agencies and the Federal Permitting Improvement Steering Committee to expedite approvals. The order frames these changes as necessary to make the United States "the most competitive nation in the world for the manufacture of safe and effective pharmaceutical products," though it includes standard language clarifying that it creates no enforceable rights and is subject to available appropriations. This regulatory streamlining approach represents a significant shift toward prioritizing pharmaceutical manufacturing capacity over what the order portrays as excessive regulatory oversight.